Cellumed Co., Ltd. (049180) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cellumed Co., Ltd. (049180:KRX), powered by AI.

Current Price
₩1,009
P/E Ratio
-1.6
Market Cap
55.5B
Sector
Healthcare
What is the Cellumed Co., Ltd. stock price forecast?

Cellumed Co., Ltd. is currently trading at ₩1,009. View real-time AI analysis on Alpha Lenz.

What is Cellumed Co., Ltd. insider trading activity?

View the latest insider trading data for Cellumed Co., Ltd. on Alpha Lenz.

What is Cellumed Co., Ltd.'s P/E ratio?

Cellumed Co., Ltd.'s P/E ratio is -1.6.

Cellumed Co., Ltd.

KRX · 049180
₩1,009
Ask about Cellumed Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Cellumed Co., Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -202.0%.

Ask for details

Company Overview

Cellumed Co., Ltd. is a biomedical company that specializes in the development and production of advanced medical products. The company focuses primarily on regenerative medicine and cell therapy technologies, seeking to provide innovative solutions for various medical conditions. Cellumed Co., Ltd. plays a key role in the healthcare and biotechnology sectors, offering products that support the treatment of serious and chronic diseases. The company's commitment to research and development positions it as a significant participant in the growing global market for biopharmaceuticals and advanced therapeutics. By leveraging cutting-edge technologies, Cellumed Co., Ltd. contributes to the advancement of medical care and improved patient outcomes. This specialized approach not only enhances its market presence but also underscores its importance in the field of innovative healthcare solutions.

CEO유인수
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees93

Company Statistics

FY 2024

Profile

₩55,451,676,567Market Cap
₩129,139,780,660Revenue
54.96MShares Out
93Employees

Margins

7.35%Gross
-17.79%EBITDA
-17.52%Operating
-24.84%Pre-Tax
-24.64%Net

Valuation

-1.56P/E
5.59P/B
0.38EV/Sales
-2.15EV/EBITDA
-22.30P/FCF

Growth (CAGR)

8.93%Rev 3Yr
48.44%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-46.55%ROA
-201.97%ROE
-44.98%ROIC

Financial Health

₩9,622,204,120Cash & Cash Equivalents
₩51,541,563,160Net Debt
675.03%Debt/Equity
N/AInterest Cov
Alpha Chat Insight

Cellumed Co., Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -202.0%.

Ask for details

Frequently Asked Questions

Cellumed Co., Ltd. (ticker: 049180) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). It has approximately 93 employees. Market cap is $55.5B.

The current price is ₩1,009 with a P/E ratio of -1.56x and P/B of 5.59x.

ROE is -201.97% and operating margin is -17.52%. Annual revenue is $129.1B.

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Cellumed Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩1,009 | Alpha Lenz